Evidence map›Paper›PMID 18650420›Full record

ArticleThe Journal of biological chemistry2008

Paclitaxel binding to human and murine MD-2.

Shanta M Zimmer, Jin Liu, Jaime L Clayton, David S Stephens, James P Snyder

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Brachytherapy via a depot of biopolymer-boundNature biomedical engineering · 2022
    Article
  11. Article
  12. HSP60-Derived Peptide as an LPS/TLR4 Modulator: AnFrontiers in cardiovascular medicine · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Tracing the evolution of novel features of human Toll-like receptor 4.Protein science : a publication of the Protein Society · 2019
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shanta M ZimmerDepartment of Chemistry, Emory University, Atlanta, Georgia 30322.
Jin LiuDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia 30322.
Jaime L ClaytonDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia 30322.
David S StephensDepartment of Chemistry, Emory University, Atlanta, Georgia 30322.
James P SnyderDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia 30322.
Emory University · US

Funding

STUDIES OF TUBULIN-INTERACTIVE ANTICANCER DRUGSR01CA069571 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI KINGSTON, DAVID GEORGE IAN · 1996 to 2008
$2.6M
MENINGOCOCCAL LIPOOLIGOSACCHARIDE &MUCOSAL PATHOGENESISR01AI033517 · NIAID · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 1993 to 2007
$1.7M
Activation of human TLR4 by endotoxin binding to MD-2K08AI060966 · NIAID · EMORY UNIVERSITY · PI ZIMMER, SHANTA M · 2004 to 2008
$574k
NCI NIH HHS R01 CA-69571NIAID NIH HHS K08 AI060966-03NIAID NIH HHS R01 AI033517-10
6 · The paper itself

Abstract

Paclitaxel (PTX) is an important cancer chemotherapeutic agent that binds to beta-tubulin and prevents mitosis through microtubule overstabilization. Recent evidence also implicates PTX in the induction of apoptosis of cancer cells via the TLR4 innate immune pathway. The TLR4 accessory protein, MD-2, is an essential component for the species-specific proinflammatory activity of PTX on murine cells. However, whether PTX binds to human MD-2 and how MD-2 and TLR4 interact with PTX are not well defined. Recombinant human MD-2 (rhMD-2) was produced in a Pichia pastoris expression system, and the interaction between rhMD-2 and PTX was assessed by an enzyme-linked immunosorbent assay to show that PTX binds rhMD-2. Formation of the latter complex was found to be dose-dependent and inhibited by anti-MD-2 antibody but not by an isotype control antibody. As measured by human tumor necrosis factor alpha production, human THP-1 monocytes expressing TLR4 and MD-2 were poorly responsive to the addition of PTX, but murine macrophages expressing TLR4 and MD-2 responded in a dose-dependent manner. Human embryonic kidney (HEK293) cells transfected with both human TLR4 and human MD-2 or human MD-2 and murine TLR4 were also poorly responsive to PTX (10 microm). However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation. To further define the structural differences for MD-2/TLR4 activation, crystal structures of both murine and human MD-2 were subjected to PTX docking by computational methods. These models indicate that PTX binds in the pocket of both human and mouse MD-2 structures. The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop. In particular, Phe(126) appears to operate as a bridge for TLR4.MD-2 dimerization in the mouse but not the human protein.

Indexed as

Models, MolecularAnimalsAntineoplastic Agents, PhytogenicBinding SitesCell LineDose-Response Relationship, DrugHumansLymphocyte Antigen 96MacrophagesMicePaclitaxelProtein BindingProtein Structure, SecondaryProtein Structure, TertiaryRecombinant ProteinsSpecies SpecificityAntineoplastic Agents, PhytogenicLY96 protein, humanLy96 protein, mouseLymphocyte Antigen 96PaclitaxelRecombinant ProteinsTLR4 protein, humanTlr4 protein, mouseToll-Like Receptor 4TubulinTumor Necrosis Factor-alpha

Identifiers

PMID18650420
PMCPMC2562052
OpenAlexW2028226782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.